SCHEMBL6523443

SCHEMBL6523443

Cc1cc(C(=O)O)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4cccc(Cl)c4)cc32)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.49
AURKA O14965 3/20 0.48
KDR P35968 5/20 0.45
MET P08581 4/20 0.45
FGFR1 P11362 4/20 0.45
MEN1 O00255 2/20 0.45
CDK2 P24941 2/20 0.45
KMT2A Q03164 2/20 0.45
PTK2B Q14289 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CCNE1 P24864 1/20 0.45
RECQL P46063 1/20 0.45
PDGFRB P09619 4/20 0.44
EGFR P00533 2/20 0.44
SRC P12931 2/20 0.44
ALK Q9UM73 2/20 0.44
PLK4 O00444 1/20 0.44
RIOK3 O14730 1/20 0.44
CASK O14936 1/20 0.44
GAK O14976 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519857 0.91 AURKA (0.56) RETAURKAKDRFGFR1MEN1
SCHEMBL147703 0.88 KDR (0.55) RETAURKAKDRMETFGFR1
SCHEMBL6516466 0.87 AKT2 (0.54) RETAURKAKDRMETFGFR1
SCHEMBL6267653 0.86 ALK (0.58) RETAURKAKDRMETFGFR1
SCHEMBL143611 0.83 MET (0.48) RETAURKAKDRMETFGFR1
SCHEMBL143213 0.83 SRC (0.48) RETKDRMETFGFR1MEN1
SCHEMBL6515665 0.82 FLT1 (0.47) RETAURKAKDRFGFR1MEN1
SCHEMBL142865 0.81 KDR (0.41) RETAURKAKDRMETFGFR1
SCHEMBL141995 0.80 RET (0.61) RETAURKAKDRFGFR1MEN1
SCHEMBL144707 0.79 AURKA (0.53) RETAURKAKDRFGFR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 RET 2074/4885AURKA 4579/4885KDR 1077/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 RET 246/4885AURKA 273/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.